Familial cold autoinflammatory syndrome
Other Names for this Disease
- Familial cold urticaria
- Familial polymorphous cold eruption
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
On this page
Individuals with familial cold autoinflammatory syndrome (FCAS) are generally advised to avoid exposure to cold temperatures. Bed rest, warmth and corticosteroids can be used to treat an acute attack. Treatment may include the use of biologic agents (drugs derived from living material) which can control the symptoms of FCAS by blocking interleukin-1; they are called selective recombinant interleukin-1 receptor agonists. Examples of these agents are rilonacept, anakinra, and canakinumab. These agents reportedly have a significant beneficial effect on quality of life for individuals with FCAS.
Last updated: 11/14/2013
- Delwyn Dyall-Smith. Familial cold autoinflammatory syndrome. DermNet NZ. March 2011; http://www.dermnetnz.org/systemic/fcas.html. Accessed 10/30/2013.
- Marwan Shinawi. Hereditary Periodic Fever Syndromes. Medscape Reference. January 11, 2013; http://emedicine.medscape.com/article/952254-overview#aw2aab6b7. Accessed 9/23/2013.
- ClinicalTrials.gov lists trials that are studying or have studied Familial cold autoinflammatory syndrome. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
Medical ProductsThe medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.
(Regeneron Pharmaceuticals, Inc.)
The FDA has approved this product to be used in this manner.
|Treatment of Cryopyrin-Assisted Periodic Syndromes (CAPS)|
|More Information about this product||Drug Information Portal|